Mechanisms of Action of Bisphosphonates as Inhibitors of Bone Resorption

  • Michael J. Rogers
  • R. Graham G. Russell
Part of the Medical Intelligence Unit book series (MIU.LANDES)

Abstract

More than 25 years have passed since it was first recognized that bisphosphonates could inhibit bone resorption.1–3 During this time, bisphosphonates have become the treatment of choice for a variety of bone diseases in which excessive osteoclast activity is an important pathological feature, including Paget’s disease of bone,4 metastatic and osteolytic bone disease, hypercalcemia of malignancy5 and, more recently, postmenopausal and other forms of osteoporosis (Fig. 7.1).6,7 However, despite the widespread clinical use of bisphosphonates, their exact mechanism of action, at both the cellular and molecular level, have not been clearly identified.

Keywords

Osteoporosis Calcitonin Colchicine Disodium Rheumatol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969; 165: 1264–1266.PubMedGoogle Scholar
  2. 2.
    Reynolds JJ, Minkin C, Morgan DB et al. The effect of two diphosphonates on the resorption of mouse calvaria in vitro. Calcif Tiss Res 1972; 10: 302–313.Google Scholar
  3. 3.
    Schenk R, Merz WA, Muhlbauer R et al. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (C12MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calc Tiss Res 1973; 11: 196–214.Google Scholar
  4. 4.
    Smith R, Russell RGG, Bishop M. Diphosphonates and Paget’s disease of bone. Lancet 1971; 1: 945–947.PubMedGoogle Scholar
  5. 5.
    Fleisch H. Bisphosphonates, pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919–942.PubMedGoogle Scholar
  6. 6.
    Storm T, Thamsborg G, Steiniche T et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. New Engl J Med 1990; 322: 1265–71.PubMedGoogle Scholar
  7. 7.
    Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73–79.PubMedGoogle Scholar
  8. 8.
    Fleisch H, Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 1962; 203: 671–675.PubMedGoogle Scholar
  9. 9.
    Fleisch H, Neuman WF. Mechanisms of calcification: role of collagen, polyphosphates, and phosphatase. Am J Physiol 1961; 200: 1296–1300.Google Scholar
  10. 10.
    Fleisch H, Russell RGG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 1966; 212: 901–903.PubMedGoogle Scholar
  11. 11.
    Francis MD. The inhibition of calcium hydroxyapatite crystal growth by polyphosphates. Calcif Tiss Res 1969; 3: 151–162.Google Scholar
  12. 12.
    Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969; 165: 1262–1264.PubMedGoogle Scholar
  13. 13.
    Fleisch HA, Russell RGG, Bisaz S et al. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1970; 1: 12–18.PubMedGoogle Scholar
  14. 14.
    Russell RGG, Muhlbauer RC, Bisaz S et al. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calc Tiss Res 1970; 6: 183–196.Google Scholar
  15. 15.
    Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates on hydroxyapatite crystals. Calc Tiss Res 1973; 11: 269–280.Google Scholar
  16. 16.
    Ebrahimpour A, Francis MD. Bisphosphonate therapy in acute and chronic bone loss: physical chemical considerations in bisphosphonate-related therapies. In: Bijvoet O, Fleisch HA, Canfield RE, Russell RGG, eds. Bisphosphonate on bones. Elsevier Science B.V., 1995.Google Scholar
  17. 17.
    Shinoda H, Adamek G, Felix R et al. Structure-activity relationships of various bisphosphonates. Calcif Tiss Int 1983; 35: 87–99.Google Scholar
  18. 18.
    Geddes AD, D’Souza SM, Ebetino FH et al. Bisphosphonates: structure-activity relationships and therapeutic implications. Bone and Mineral Res 1994; 8: 265–306.Google Scholar
  19. 19.
    Schenk R, Eggli P, Fleisch H et al. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calc Tiss Int 1986; 38: 342–349.Google Scholar
  20. 20.
    Muhlbauer RC, Bauss F, Schenk R et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Min Res 1991; 6: 1003–1011.Google Scholar
  21. 21.
    Boonekamp PM, Löwik CWGM, van der Wee-Pals LJA et al. Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone and Mineral 1987; 2: 29–42.PubMedGoogle Scholar
  22. 22.
    Van der Pluijm G, Binderup L, Bramm E et al. Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo. J Bone Miner Res 1992; 7: 981–986.PubMedGoogle Scholar
  23. 23.
    Sietsema WK, Ebetino FH, Salvagno AM et al. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exptl Clin Res 1989; 15: 389–396.Google Scholar
  24. 24.
    Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745–751.PubMedGoogle Scholar
  25. 25.
    Ebetino FH, Russell RGG. Metabolic bone disease: current therapies and future prospects with bisphosphonates and other agents. In: Sarei S, Mechoulam R, Agranat I, eds. Trends in Medicinal Chemistry ‘90. Oxford: Blackwell Scientific Publications, 1992: 293–298.Google Scholar
  26. 26.
    Mundy GR, Roodman GD. Osteoclast ontogeny and function. Bone and Mineral Res 1987; 5: 209–279.Google Scholar
  27. 27.
    Zaidi M, Towhidul Alam ASM, Shankar VS et al. Cellular biology of bone resorption. Biol Rev 1993; 68: 197–264.PubMedGoogle Scholar
  28. 28.
    Horton MA, Davies J. Perspectives: Adhesion receptors in bone. J Bone Miner Res 1989; 4: 803–808.PubMedGoogle Scholar
  29. 29.
    Davies J, Warwick J, Totty N et al. The osteoclast functional antigen implicated in the regulation of bone resorption is biochemically related to the vitronectin receptor. J Cell Biol 1989; 109: 1817–1826.PubMedGoogle Scholar
  30. 30.
    Lakkakorpi PT, Vaananen HK. Kinetics of the osteoclast cytoskeleton during the resorption cycle in vitro. J Bone Miner Res 1991; 6: 817–826.PubMedGoogle Scholar
  31. 31.
    Baron R, Neff L, Louvard D et al. Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol 1985; 101: 2210–2222.PubMedGoogle Scholar
  32. 32.
    Blair HC, Teitelbaum SL, Ghiselli R et al. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 1989; 245: 855–857.PubMedGoogle Scholar
  33. 33.
    Väänänen HK, Karhukorpi E-K, Sundquist K et al. Evidence for the presence of a proton pump of the vacuolar H`-ATPase type in the ruffled borders of osteoclasts. J Cell Biol 1990; 111: 1305–1311.PubMedGoogle Scholar
  34. 34.
    Baron R. Molecular mechanisms of bone resorption by the osteoclast. Anat Rec 1989; 224: 317–324.PubMedGoogle Scholar
  35. 35.
    Bisaz S, Jung A, Fleisch H. Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives. Clin Sci Mol Med 1978; 54: 265–272.PubMedGoogle Scholar
  36. 36.
    Sato M, Grasser W, Endo N et al. Bisphosphonate action. Alendronate localisation in rat bone and effects on osteoclast ultra-structure. J Clin Invest 1991; 88: 2095–2105.PubMedGoogle Scholar
  37. 37.
    Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts and bone. Calcif Tiss Int 1991; 49: 407–415.Google Scholar
  38. 38.
    Rowe DJ, Hausmann E. The alteration in osteoclast morphology by diphosphonates in bone organ culture. Calc Tiss Res 1976; 20: 53–60.Google Scholar
  39. 39.
    Rowe DJ, Hausmann E. The effects of calcitonin and colchicine on the cellular response to diphosphonate. Br J Exp Path 1980; 61: 303–309.Google Scholar
  40. 40.
    Rowe DJ, Hays SJ. Inhibition of bone resorption by difluoromethylene diphosphonate in organ culture. Metab Bone Dis and Rel Res 1983; 5: 13–16.Google Scholar
  41. 41.
    Flanagan AM, Chambers TJ. Dichloromethylenebisphosphonate (C12MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone. Bone and Mineral 1989; 6: 33–43.PubMedGoogle Scholar
  42. 42.
    Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980; 68: 251–306.PubMedGoogle Scholar
  43. 43.
    Bortner CD, Oldenburg NBE, Cidlowski, JA. The role of DNA fragmentation in apoptosis. Trends Cell Biol 1995; 5: 21–26.PubMedGoogle Scholar
  44. 44.
    Hughes DE, Wright KR, Uy HL et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 1478–1487.PubMedGoogle Scholar
  45. 45.
    Selander KS, Härkönen PL, Mönkkönen J et al. The mode of death induced by clodronate in isolated osteoclasts is apoptosis. Calc Tiss Int 1995; 56: 450 (abstract).Google Scholar
  46. 46.
    Hughes DE, Wiltschke K, Mundy GR et al. Estrogen promotes osteoclast apoptosis in vitro and in vivo. Bone 1995; 16 (S1): 93S (abstract).Google Scholar
  47. 47.
    Hughes DE, Wright KR, Mundy GR et al. TGFß1 induces osteoclast apoptosis in vitro. J Bone Miner Res 1994; 9 (Suppl 1): S138 (abstract).Google Scholar
  48. 48.
    Carano A, Teitelbaum SA, Konsek JD et al. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990; 85: 456–461.PubMedGoogle Scholar
  49. 49.
    Felix R, Fleisch H. Increase in alkaline phosphatase activity in cal-varia cells cultured with diphosphonates. Biochem J 1979; 183: 73–81.PubMedGoogle Scholar
  50. 50.
    Morgan DB, Monod A, Russell RGG et al. Influence of dichloromethylene diphosphonate and calcitonin on bone resorption, lactate production and phosphatase and pyrophosphatase content of mouse calvaria treated with parathyroid hormone in vitro. Calc Tiss Res 1973; 13: 287–294.Google Scholar
  51. 51.
    Fast DE, Felix R, Dowse C et al. The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture. Biochem J 1978; 172: 97–107.PubMedGoogle Scholar
  52. 52.
    Ende JJ, van Rooijen HJM. Some effects of EHDP and C12MDP on the metabolism of mouse calvaria in tissue culture. Proc Kon Ned Akad Wet 1979; C82: 43–54.Google Scholar
  53. 53.
    Amin D, Cornell SA, Gustafson SK et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 1992; 33: 1657–1663.PubMedGoogle Scholar
  54. 54.
    Felix R. Studies with isolated cells and systems. In: Bijvoet O, Fleisch HA, Canfield RE, Russell RGG, eds. Bisphosphonate on Bones. Elsevier Science B.V. 1995: 189–204.Google Scholar
  55. 55.
    Miller SC, Jee WSS. The effect of dichloromethylene diphosphonate, a pyrophosphate analog, on bone and bone cell structure in the growing rat. Anatomical Rec 1979; 193: 439–462.Google Scholar
  56. 56.
    Plasmans CMT, Jap PHK, Kuijpers W et al. Influence of a diphosphonate on the cellular aspect of young bone tissue. Calcif Tissue Im 1980; 32: 247–256.Google Scholar
  57. 57.
    Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990; 5: 31–40.PubMedGoogle Scholar
  58. 58.
    Murakami H, Takahashi N, Sasaki T et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995; 17: 137–144.PubMedGoogle Scholar
  59. 59.
    Boyce BF, Yoneda T, Lowe C et al. Requirement of pp60src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992; 90: 1622–1627.PubMedGoogle Scholar
  60. 60.
    Schmidt A, Opas E, Rutledge SJ et al. Alendronate inhibition of protein tyrosine phosphatase activity. Bone 1995; 17: 604 (abstract).Google Scholar
  61. 61.
    Murakami H, Takahashi N, Udagawa N et al. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone 1995; 16 (S1): 114S (abstract).Google Scholar
  62. 62.
    David P, Nguyen H, Barbier A et al. Tiludronate is a potent and specific inhibitor of the osteoclast vacuolar H’ ATPase. Bone 1995; 16 (S1): 166S (abstract).Google Scholar
  63. 63.
    Zimolo Z, Wesolowski G, Rodan GA. Acid extrusion is induced by osteoclast attachment to bone. J Clin Invest 1995; 96: 2277–2283.PubMedGoogle Scholar
  64. 64.
    Felix R, Russell RGG, Fleisch H. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Acta 1976; 429: 429–438.PubMedGoogle Scholar
  65. 65.
    Lerner UH, Larsson A. Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro. Bone 1987; 8: 179–189.PubMedGoogle Scholar
  66. 66.
    Löwik C, van der Pluijm G. Mechanisms of action of bisphosphonates: studies with bone culture systems. In: Bijvoet O, Fleisch HA, Canfield RE, Russell RGG, eds. Bisphosphonate on Bones. Elsevier Science B.V. 1995: 155–170.Google Scholar
  67. 67.
    Hughes DE, MacDonald BR, Russell RGG et al. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989; 83: 1930–1935.PubMedGoogle Scholar
  68. 68.
    Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MLL et al. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone and Mineral 1986; 1: 27–39.PubMedGoogle Scholar
  69. 69.
    Löwik CWGM, van der Pluijm G, van der Wee-Pals LJA et al. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res 1988; 3: 185–192.PubMedGoogle Scholar
  70. 70.
    Papapoulos SE, Hoekman K, Lowik CWGM et al. Application of an in vitro model and a clinical protocol in the assesment of the potency of a new bisphosphonate. J Bone Miner Res 1988; 4: 775–781.Google Scholar
  71. 71.
    Guenther HL, Guenther HE, Fleisch H. Effects of 1-hydroxyethane1,1-diphosphonate and dichloromethanediphosphonate on rabbit articular chondrocytes in culture. Biochem J 1979; 184: 203–214.PubMedGoogle Scholar
  72. 72.
    D’Souza SM, Orcutt CM, Ibbotson KJ. Inhibitory effects of bisphosphonates on rat osteoblast-like cells: correlation with antiresorptive potency. J Bone Miner Res 1990; 5: S90 (abstract).Google Scholar
  73. 73.
    Sahni M, Guenther H, Fleisch H et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993; 91: 2004–2011.PubMedGoogle Scholar
  74. 74.
    Vitte C, Fleisch H, Guenther HL. Osteoblasts mediate the bisphosphonate inhibition on bone resorption through synthesis of an inhibitor of osteoclastic resorption. Bone 1995; 17: 602 (abstract).Google Scholar
  75. 75.
    Yu X, Scholler J, Foged NT. Pretreatment of an osteoblast-like cell line with bisphosphonates inhibits its PTH-stimulated induction of osteoclastic bone resorption. J Bone Miner Res 1994; 9 (Suppl 1): S232 (abstract).Google Scholar
  76. 76.
    Niskikawa M, Akatsu T, Katayama Y et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclastic cell formation in mouse marrow culture. Bone 1995; 16 (S1): 167S (abstract).Google Scholar
  77. 77.
    Stevenson PH, Stevenson JR. Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages. Calcif Tiss Int 1986; 38: 227–233.Google Scholar
  78. 78.
    Cecchini MG, Felix R, Fleisch H et al. Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res 1987; 2: 135–142.PubMedGoogle Scholar
  79. 79.
    Cecchini MG, Fleisch H. Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Miner Res 1990; 5: 1019–1027.PubMedGoogle Scholar
  80. 80.
    Mönkkönen J, Taskinen M, Auriola SOK et al. Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound and free bisphosphonates in vitro. J Drug Targetting 1994; 2: 299–308.Google Scholar
  81. 81.
    De Vries E, van der Weij JP, v.d. Veen CJP et al. In vitro effectGoogle Scholar
  82. of (3-amino-l-hydroxypropylidene)-1,1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation. Immunology 1982; 47: 157–163.Google Scholar
  83. 82.
    Chambers TJ. Diphosphonates inhibit bone resorption by macrophages in vitro. J Pathol 1980; 132: 255–262.PubMedGoogle Scholar
  84. 83.
    Reitsma PH, Teitelbaum SL, Bijvoet OLM et al. Differential action of the bisphosphonates (3-amino-l-hydroxypropylidene)-1,1bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (C12MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest 1982; 70: 927–933.PubMedGoogle Scholar
  85. 84.
    Rogers MJ, Chilton KM, Coxon FP et al. Biosphosphonates induce apoptosis in mouse macrophage-like cells by a nitric oxide independent mechanism. J Bone Miner Res 1996; in press.Google Scholar
  86. 85.
    Coxon FP, Russell RGG, Rogers MJ. Pathways of bisphosphonateinduced apoptosis in murine macrophage-like cells. Bone 1995; 17: 600 (abstract).Google Scholar
  87. 86.
    Markkula R, Repo, H, Leirisal M et al. Effect of dichloromethylene diphosphonate (C12MDP) on immune function in breast cancer patients with bone metastases. Cancer Immunol Immunother 1983; 15: 159–161.PubMedGoogle Scholar
  88. 87.
    Adami S, Bhalla AK, Dorizzi R et al. The acute-phase response after bisphosphonate administration. Calcif Tiss Int 1987; 41: 326–331.Google Scholar
  89. 88.
    Schweitzer DH, Oostendorp-van de Ruit M, van der Pluijm G et al. Interleukin-6 and the acute phase response during treatment of patients with Paget’s disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995; 10: 956–962.PubMedGoogle Scholar
  90. 89.
    Pioli G, Hughes DE, Mian M et al. Bisphosphonates stimulate the production of cytokines by human peripheral blood mononuclear cells in vitro. Calcif Tiss Int 1990; 46 (Suppl. 2): A54 (abstract).Google Scholar
  91. 90.
    Miller SC, Jee WSS, Kimmel DB et al. Ethane-1-hydroxy-1,1diphosphonate (EHDP) effects on incorporation and accumulation of osteoclast nuclei. Calc Tissue Res 1977; 22: 243–252.Google Scholar
  92. 91.
    Evans RA, Howlett CR, Dunstan CR et al. The effect of longterm low-dose diphosphonate treatment on rat bone. Clin Orthop Rel Res 1982; 165: 290–299.Google Scholar
  93. 92.
    Marshall MJ, Holt I, Davie MWJ. Osteoclast recruitment in mice is stimulated by (3-amino-l-hydroxypropylidene)-1,1-bisphosphonate. Calcif Tissue Int 1990; 52: 21–25.Google Scholar
  94. 93.
    Marshall MJ, Wilson AS, Davie MWJ. Effects of (3-amino-1hydroxypropylidene)-1,1-bisphosphonate on mouse osteoclasts. J Bone Miner Res 1993; 5: 955–962.Google Scholar
  95. 94.
    Katoh Y, Tsuji H, Matsui K et al. Effects of ethane-l-hydroxyl,1-diphosphonate on cell differentiation and proteoglycan and calcium metabolism in the proximal tibia of young rats. Bone 1991; 12: 59–65.PubMedGoogle Scholar
  96. 95.
    Endo Y, Nakamura M, Kikuchi T et al. Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes and osteoclasts in vivo. Calcif Tissue Int 1993; 52: 248–254.PubMedGoogle Scholar
  97. 96.
    Francis MD, Flora L, King WR. The effects of disodium ethane-1hydroxy-1,1-diphosphonate on adjuvant induced arthritis in rats. Calc Tiss Res 1972; 9: 109–121.Google Scholar
  98. 97.
    Francis MD, Horancik K, Boyce RW. NE 58095 A diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React 1989; 11: 239–252.PubMedGoogle Scholar
  99. 98.
    Flora L. Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 1979; 22: 340–346.PubMedGoogle Scholar
  100. 99.
    Barbier A, Breliere JC, Remandet B et al. Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Ann Rheum Dis 1986; 45: 67–74.PubMedGoogle Scholar
  101. 100.
    Dunn CJ, Galinet LA, Wu H et al. Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates. J Pharmacol Exp Ther 1993; 266: 1691–1698.PubMedGoogle Scholar
  102. 101.
    Bijvoet OLM, Frijlink WB, Jie K et al. APD in Paget’s disease of bone. Role of the mononuclear system? Arthritis Rheum 1980; 23: 1193–1204.PubMedGoogle Scholar
  103. 102.
    Van Rooijen N. The liposome mediated macrophage `suicide’ technique. J Immunol Methods 1989; 124: 1–6.PubMedGoogle Scholar
  104. 103.
    Van Rooijen N, Kors N, van den Ende M et al. Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate. Cell Tissue Res 1990; 260: 215–222.PubMedGoogle Scholar
  105. 104.
    Huitinga I, van Rooijen N, de Groot CJA et al. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J Exp Med 1990; 172: 1025–1033.PubMedGoogle Scholar
  106. 105.
    Van Lent PLEM, van den Bersselaar L, van den Hoek AEM et al. Reversible depletion of synovial lining cells after intraarticular treatment with liposome encapsulated dichloromethylene diphosphonate. Rheumatol Int 1993; 13: 21–30.PubMedGoogle Scholar
  107. 106.
    Kinne RW, Schmidt-Weber CB, Hoppe R et al. Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum 1995; 38: 1777–1790.PubMedGoogle Scholar
  108. 107.
    Felix R, Guenther HL, Fleisch H. The subcellular distribution of [14C]dichloromethylenebisphosphonate and [14C] 1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. Calcif Tiss Int 1984; 36: 108–113.Google Scholar
  109. 108.
    Chestnut MH, Rogers MJ, Watts DJ et al. Cellular uptake of bisphosphonates: localisation using fluorescently-labelled alendronate. Bone 1995; 17: 599 (abstract).Google Scholar
  110. 109.
    Mönkkönen J, Heath TD. The effects of liposome-encapsulated and free clodronate on the growth of macrophage-like cells in vitro: the role of calcium and iron. Calcif Tissue Int 1993; 53: 139–146.PubMedGoogle Scholar
  111. 110.
    Rogers MJ, Watts DJ, Russell RGG et al. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mould Dictyostelium discoideum. J Bone Miner Res 1994; 9: 1029–1039.PubMedGoogle Scholar
  112. 111.
    Rogers MJ, Xiong X, Brown RJ et al. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol Pharm 1995; 47: 398–402.Google Scholar
  113. 112.
    Rogers MJ, Xiong X, Brown RJ et al. Alterations to the phosphonate groups of bisphosphonates decrease their potency as inhibitors of bone resorption and as inhibitors of Dictyostelium growth. Bone and Mineral 1994; 25 (Suppl. 1): S69 (abstract).Google Scholar
  114. 113.
    Xiong X, Rogers MJ, Ji X, Russell RGG et al. Inhibition of growth of Dictyostelium amoebae is dependent on the cellular uptake of bisphosphonates by pinocytosis. Bone 1994; 15: 246 (abstract).Google Scholar
  115. 114.
    Rogers M, Russell RGG, Blackburn GM et al. Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. Biochem Biophys Res Commun 1992; 189: 414–423.PubMedGoogle Scholar
  116. 115.
    Rogers MJ, Ji X, Russell RGG et al. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem Journal 1994; 303: 303–311.Google Scholar
  117. 116.
    Michael WR, King WR, Wakim, JM. Metabolism of disodium ethane-l-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey. Toxicol Appl Pharmacol 1972; 21: 503–515.PubMedGoogle Scholar
  118. 117.
    Frith JC, Russell RGG, Blackburn GM et al. The anti-resorptive drug clodronate is metabolised to a non-hydrolysable ATP analogue by mammalian cells in vitro. Biochem Soc Trans 1996; 24; in press (abstract).Google Scholar
  119. 118.
    Rogers MJ, Brown RJ, Modkin V et al. Bisphosphoonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 1996; in press.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • Michael J. Rogers
  • R. Graham G. Russell

There are no affiliations available

Personalised recommendations